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ABSTRACT

An abstract of the thesis of Rosemary Ann Lown for the Master of
Science in Biology, presented May 18, 1994.

Title:

Investigations of Factors Affecting the Transcriptional
Regulation of Herpes Simplex Virus Type 1

~'Y

(Leaky-Late)

Genes.

Herpes simplex virus type 1 (HSV-1) is a virus commonly
causing cold sores in humans, however, virulent infections are known
to produce debilitating encephalitis and death.
HSV-1 transcription is carried out by the host cell RNA
polymerase II in a tightly regulated temporal cascade.

The first

genes transcribed, the a genes, are activated in the absence of viral
DNA synthesis.

Transcription of the other temporal classes, the

p, py,

and y genes is dependent upon the protein products of the a genes
for activation.
The purpose of this study was to investigate the factors that
contribute to this rigid regulation of HSV-1 transcription.

This

investigation sought to identify some of the cellular and viral
transcription factors that activate transcription of genes of the later
kinetic classes.

Two separate approaches were utilized in these

2

investigations.

1)

In vitro transcription using a soluble, cell free

system to study the transcriptional regulation of the VP5 gene, and
2)

DNA competition binding assays to identify and characterize the

protein-DNA complexes resulting from interaction between the cisacting DNA sequences of the VP5 gene, other viral genes, and the
proteins that bind to them.
Attempts at in vitro transcription of
unsuccessful.

~, ~y,

and y genes were

Because these genes require a products for activation,

it was necessary to prepare nuclear extracts from infected cells.
However, HSV-1 contains endogenous RNase activities which are
components of the biochemical machinery by which the virus directs
host transcription to the synthesis of viral molecules.

The uses of

virus deficient in the host shut-off function and various drugs were
unsuccessful.
Previous work in the Millette laboratory demonstrated a
sequence in the VP5 promoter that played a significant role in the up
regulation of expression of that gene.

DNA binding competition

studies using a number of HSV-1 sequences exhibiting partial
homology to this sequence demonstrated that these sequences all
compete for the binding of the same protein factor.

Similarly, a piece

of the human immunodeficiency virus (HIV) exhibiting a seven base
pair homology also exhibited weak competition.
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CHAPTER I

INTRODUCTION

Viruses are simple, submicroscopic structures capable of
infecting an enormous variety of organisms.

These noncellular

genetic elements characteristically have an extracellular form that 1s
the infective phase of the virus.

The basic simplicity of viruses

makes them obligate parasites, requiring host cells to carry out
replicative processes.
Typical viral composition includes a nucleic acid genome and at
most a few proteins contained within a proteinaceous capsid.

These

submicroscopic parasites have the capacity to invade a cell and alter
normal processes in a matter of minutes.

However, the mechanisms

by which viruses commandeer and alter the usual host physiology is
at best poorly understood.
Investigating viral systems allows a researcher access to two
levels of analysis:

In addition to studying viruses themselves, it is

possible for a researcher to utilize viruses to perturb the normal cell
physiology without causing immediate cell death.

Therefore it

becomes possible to study normal cellular processes utilizing a viral
parasite.
Herpes simplex virus type 1 (HSV-1) is a common pathogen
that afflicts humans.

Most frequently HSV-1 infections result in cold
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sores;

however, these viruses are also known to cause severe,

debilitating and frequently fatal encephalitis, blindness and
disfiguring scarring.

Once a productive infection is established, HSV-

1 enters the sensory neurons of the infected cells and produces a
latent infection in the cell body of the compromised neuron.

Once

sustained, latent infections persist throughout the lifetime of the
host.

Latent infections can periodically give rise to a lytic infection in

the epithelial cells innervated by the affected nerve.

Virus Structure
In comparison to cells, viruses are structurally relatively
simple.

All herpesviruses exhibit the same four basic anatomic

elements:
(figure 1).

A membranous envelope, a tegument, a capsid and a core
The herpesvirus envelope is derived from the inner

lamella of the nuclear membrane in the host cell.

This viral envelope

is composed of lipids, proteins and the polyamines spermine and
spermidine (22).

Despite the cellular origin of the viral envelope, it

is remarkable for its lack of host proteins.

Instead, the membrane-

bound proteins found in the envelope are virally encoded
glycoproteins.

The mechanism by which the host cell nuclear

envelope is modified to exclude normal host proteins and incorporate
only viral proteins is not clear.

The viral envelope glycoproteins are

believed to be transported to the nuclear membrane via a process
involving the Golgi apparatus.

What is clearly understood is that
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viral glycoproteins are the means by which a virus attaches itself to
and enters a cell.
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Fi2ure 1. Structure of herpes simplex virus type 1. The
toroidal DNA genome is contained within an icosahedral capsid.
The capsid is surrounded by tegument contained within the
host derived envelope. Viral receptors protrude from the
envelope layer. Legend: A. Envelope. B. Capsid. C. Viral
DNA. D. Tegument. E. Glycoproteins.

Separating the viral envelope from the underlying capsid is the
amorphous tegument.

The components of this structure have not

been thoroughly defined.

However, it is known that a number of
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viral proteins are typically found in the tegument, particularly the

transcription regulatory factors atrans-inducing factor (aTIF), ICP4,
ICPO, ICP27, and the viral host shutoff (VHS) protein (52).
Beneath the tegument, the proteinaceous capsid houses the
genetic material.

The capsid is icosahedral in shape, and consists of

seven virally-encoded proteins.

It has been observed that the actual

protein composition of the capsid varies somewhat depending on
whether or not the viral DNA has been packaged within it and
whether or not it has been enveloped (52).

Within the capsid, the

DNA is toroidal.
The genome of HSV-1 is a linear, double-stranded molecule of
DNA approximately 150 kilobase pairs (kbp) in size.
(guanine plus cytosine) content is high (68% - 69%).

The G+C
Structurally, the

DNA appears to consist of two components, the long (L) and short (S)
segments, covalently linked end-to-end (figure 2).

Each component

contains a length of unique DNA sequence wedged between regions
of inverted repeats (IRs) designated ab and a'b' flanking the long
sequence, and a'c' and ac

flanking the short sequence.

long (UL) region has a length of approximately 108 kbp.

The umque
The unique

short (Us) sequence is 13 kbp in length. The long terminal repeats
(TRL) and short terminal repeats (TRs) are roughly 9.2 kbp and 6.6
kbp respectively.

The IRs themselves contain elements that are

highly conserved, but they can exhibit some variability with respect
to the number of internal repeated elements.

The region of covalent

linkage between the L and S components is the so called hinge
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region.

During replication, the L and S components can invert

relative to one another at the hinge thus giving rise to four structural
isomers (52).

a....

b
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C> Ir
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Terminal
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Internal
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short
6h l<Bp

c_

unique
ShOrt

region
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snort
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2. The genome of HSV-1 illustrating the elements of the
long (L) and short (S) components. The inverted repeats ab
and a'b' flank the L component, and a'c' and ac flank the S
component. The hinge region is located between the a'
inverted repeats. Modified from Fields and Knipe (52).

Herpesvirus Replicative Cycle
The HSV-1 replication cycle begins with the attachment of the
virion to receptors located in the host cell membrane.

Particularly,

heparan sulfate proteoglycans are recognized in one of the initial
binding events (68).

This initial attachment requires either (or

both) viral glycoprotein B (gB) or glycoprotein C (gC) (43, 52).

The

initial stage of penetration is dependent upon the viral glycoproteins
gB, gC and gH:L. Penetration of the virus into the cell interior is
accomplished by virally-directed fusion of the HSV-1 envelope and
the cell membrane, a process that requires the viral glycoproteins gB
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and gD.

Once fusion between the virion and the cell membrane has

occurred, the viral nucleocapsid and tegument enters the cell
cytoplasm.
removed.

In the process of penetration, the viral envelope is
(52).

The next event in HSV-1 replication is the transport of the viral
nucleocapsids to the nuclear membrane by a mechanism thought to
involve the cellular cytoskeleton.

Upon arriving at the nuclear pores,

the viral DNA is released into the nucleoplasm (52).
Following the initial viral infection, there is a rapid shut off of
host macromolecule synthesis and a switch of the cellular machinery
to the production of viral proteins.

This conversion from cellular

macromolecule synthesis to viral macromolecule synthesis occurs in
several stages.

First, host polypeptide synthesis is suppressed

coincident with the disaggregation of the infected cell polyribosomes.
This is followed by a subsequent degradation of host cell mRNAs.
The onset of viral polypeptide synthesis is associated with the
formation of new, viral-specific polyribosomes that have a size
distribution that is different from that of the host

(32, 61 ).

The

initial shut-off, the disaggregation of host polyribosomes, is mediated
by a virion structural component that is carried into the host cell m
the tegument of the virus, the VHS protein.

This vhs

function

enables the virus to remove host mRNA from the pool of translatable
message, thus aiding the virus in switching from host protein
synthesis to virion protein synthesis (30, 31 ).

Additionally, data
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indicates that the vhs

gene product facilitates the transition between

regulatory classes by destroying a and B mRNAs (61).
The complete degradation of host mRN A requires expression of
viral genes and is a secondary phenomenon coded for by a viral gene
of the B or y class.

It can occur without the prior host shut off events.

(The viral host protein shut off is not required for the production of
viral progeny.[32]).
The transcription of HSV-1 genes is a coordinately regulated
process in which the several kinetic classes of genes are transcribed
m a temporal cascade by the host RNA polymerase II (figure 3) (64,

67).
The a genes, the first kinetic class, consist of five genes ( aO, a4,
a22, a27 and a47).

These genes are transcribed in the absence of

viral protein synthesis.

As a group most of these genes map in the

long and short repeat regions of the HSV-1 DNA molecule, with aO
and a4 present in two copies per genome.

Typically, the a genes

encode transcription regulatory factors and are required for the
synthesis of the polypeptide products of subsequent kinetic classes
(52).
Transcription of the a genes themselves is induced by the viral
trans-activating protein, aTIF (VP16) (24, 25).

As previously

mentioned, a TIF is a constituent protein of the tegument.

As such it

is released from the virus after penetration into the cell.

This

protein is transported to the nucleus independently of the viral DNA
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and interacts, not with a cis-acting regulatory DNA sequence, but

with a cellular transcription factor, OTF-1, which in turn binds
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Figure 3.

The replicative cycle of HSV-1 (49).

to a specific site in the viral a promoter.

This sequence, located less

than 400 bp upstream from the cap site, is unique to and
characteristic of a promoters.

OTF-1 binding to this region initiates

transcription of a genes (24, 25, 38, 39, 49). Expression of a
polypeptides peaks two to four hours post infection.
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Viral DNA replication and nucleotide synthesis are the major

events associated with B protein expression and require prior
expression of a proteins.
infection.

Some B products appear very early in

These have been designated the B1 genes, and include the

large subunit of the viral ribonucleotide reductase and the major
DNA binding protein.

However, unlike a genes, they require viral

transcription factors for activation.

The protein products of B genes

are generally involved in nucleotide and viral nucleic acid
metabolism and viral DNA replication, e.g., thymidine kinase (tk),
ribonucleotide reductase and the viral DNA polymerase among others
( 11, 28 ).

Peak polypeptide production of B genes occurs five to seven

hours following infection.
Inclusion of viral genes in the third kinetic class, the y genes, is
somewhat arbitrary.

Although expression of the entire complement

of these genes requires viral DNA synthesis, the py or 'YI genes of
HSV-1 are expressed at low levels before DNA replication, and at
high levels following DNA replication (11, 64 ).

In contrast, the true

late, y or 'Y2 genes, require prior DNA replication for their expression.
The mechanism of activation of both is poorly understood.

It is know

that a genes are required for initial onset of P'Y and y transcription
(8).

However, it has been observed that viral DNA replication is

required for maximum py and y. In cells in which HSV-1 replication
has occurred, the mRN As and proteins for the py and y genes are
among the most numerous.

Many of the P'Y and y genes code for viral
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structural proteins, e.g. the major capsid protein VP5, and a number
of glycoproteins (gB, gC, and gD) (52, 55).
Following transcription, the viral mRNAs are capped,
methylated, polyadenylated and transported to the cytoplasm.
Protein synthesis is carried out by the host translation apparatus,
apparently on both free and endoplasmic reticulum-bound
polyribosomes.

Following translation and post-translational

processing (splicing, glycosylation, etc.), again carried out by host
enzymes, virion proteins are transported back into the nucleus for
assembly into mature progeny virus.

The mechanism by which the

protein constituents of HSV-1 are transported has not been defined,
but assembly seems to occur by a spontaneous process akin to that
described for the large bacteriophages, e.g., T4 (52).
Viral DNA replication is first detected about three hours post
infection.

Viral DNA isolated early after the onset of replication

yields both linear branched and circular forms of DNA.

Indications

are, however, that late in replication, HSV-1 is copied via the rolling
circle mechanism from three origins of replication.

Two origins are

contained within the inverted repeats of the S segment, and the third
in the approximate center of the unique long (UL) region.

It has

been observed that deletion of one of the S origins and the L origin
does not adversely affect the ability of the virus to replicate (51 ).
Production of mature infectious viral particles takes place in
the nucleus.

Capsids are formed from the proteins previously

transported into the nucleus from the cytoplasm.

Genome lengths of
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DNA are processed and packaged into the empty capsids.

It has been

observed that, late in infection, the nuclear envelope typically
contains areas of thickened, concave or convex patches that contain
virion proteins, and that viral envelopment occurs at these patches.
The DNA-filled viral capsids attach to the modified areas of the inner
lamella of the nuclear envelope and bud through, encasing in the
inner membrane (figure 3).

Enveloped capsids then pass into the

endoplasmic reticulum and are ultimately conveyed into the
extracellular space.

Production of progeny virus necessarily results

in the destruction of the host cell.

Latency
One of the most puzzling aspects of an HSV-1 infection is the
phenomenon of latency, that is, the ability of the virus to assume a
quiescent state in host sensory neurons.

Once latency is established,

the virus can remain dormant for years, only to erupt into a fully
lytic infection following some physiological trigger.
Like so many aspects of the herpesvirus life cycle, the events
of latency are obscure.

What is known is that HSV-1 enters the

sensory neurons associated with the infected cells.

The capsids are

transported to the nuclei of the neurons in the trigeminal nerve.
Studies on latently infected neurons reveal only one set of viral
transcripts, designated LAT RNAs (for latency-associated transcripts),
that accumulates abundantly in the nuclei.

These are transcribed

from the terminal repeat of the unique long region of the herpes
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genome and are at least partially complementary to the 3' end of

ICPO (63).

The function of these latency RNAs is currently under

intense investigation by many laboratories and their role in
maintaining latent viral infections and possibly in viral reactivation
to productive infection is still obscure.
Once established, the HSV-1 latent infection remains
throughout the life of the host.

Reactivation of the virus can result

either from some local stimulus to the infected nerve, such as mJury
to the tissue, or a systemic stimulus, e.g., emotional stress,
menstruation, etc.

Structure of Eukaryotic Genes
Regulation of transcription in eukaryotic systems is intricate
and details are only slowly becoming understood.

A generalized

pattern of required DNA regulatory sequences has painstakingly
been constructed by many researchers over the years.

It is known

that genes of multicellular organisms contain both upstream and
downstream cis-acting sequences that bind a variety of trans-acting
protein factors.
Cis-acting sequences include the TAT A box, a TA-rich region
located 30 base pairs (bp) upstream (-30) from the transcription
start site.

Proteins necessary for starting transcription of protein

coding genes include transcription factor-HD (TFnD), now called TBP
(for TAT A binding protein) and TFAs (for TBP-associated factors).
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RNA polymerase II and various accessory proteins (TFnB, TFnE,
TFnF, and TFnA) are also required (34).
Additionally, activators are required to ensure normal
transcription in many genes.

These cis-acting sequences may include

a CCAAT box which is generally found at or near -80 from the
transcription start site.

However, the CCAAT box can function at

distances that vary with respect to the start site and it can function
in either orientation.

This regulatory sequence is bound by proteins

that form heterodimers.

Each protein contributing to the

heterodimer weakly binds the CCAAT DNA alone, but strongly binds
when dimerized.
Other activators include upstream activating sequences (U AS)
which are necessary for maximal transcription. Features common to
UAS include a location near the gene and a 15 to 20 bp segment that
is bound by protein.

Additionally, in mammalian genes, these UAS

are often present in multiple copies and frequently exhibit dyad
symmetry.

Examples include the GC boxes, regions containing the

consensus sequence GGGCGG, usually found within 200 bp of the
transcription start site.

These are known to be bound by stimulatory

protein 1 (Spl) (34).
One last category of activators is the set of enhancers.

These

cis-acting sequences differ from other activators in that they can be
separated by large distances from the start site and can be located
either upstream or downstream.

Otherwise, enhancers exhibit

characteristics found in sequences in the promoter region (34 ).
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Viral promoters must meet two disparate requirements.

They

must be similar enough to host promoters to allow the host
transcription factors to recognize and transcribe the viral genes.
However, the viral promoters must be sufficiently different from the
host promoters to allow independent regulation of the viral genes.
Both host and viral promoters contain cis-acting sequences that bind
a number of host trans-acting factors:
Spl and NF-1 consensus sequences.

TAT A boxes, CCAAT boxes,
The trans-acting elements

include both cellular transcription proteins that interact with these
sequences, as well as virally encoded proteins, i.e., a4.

The Problem
VP5 is the major capsid protein of HSV-1.
leaky-late

(~y

Kinetically, it is a

or yI) gene, and consequently requires a gene products

for transactivation (10).

The VP5 promoter is typical of eukaryotic

genes in that many of the cis-acting sequences are present, including
a TATA box, a CCAAT box, Spl boxes, and NF-1/CTF at -75.
Additionally, a positive regulatory sequence in the non translated
region of the VP5 leader is located 50 bp downstream (+50) from the
cap site (64).

It has been well documented that viral regulatory

factors are an absolute requirement for expression of VP5 ( 14 ).
The polypeptide product of VP5 is not expressed significantly
m the early stages of the HSV-1 replicative cycle, but is absolutely
essential in high concentration late in infection to ensure the
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production of large numbers of progeny virus.

Therefore, the virus

must have some mechanism by which this gene is up-regulated.
In this context, the Millette laboratory has been working to
elucidate some of the transcriptional controls involved in gene
regulation.

The goal has been to identify the cellular and viral

transcription factors that up-regulate VP5 expression following virus
infection
As previously noted, in order to effectively direct the host
transcription mechanism away from producing cell proteins toward
generating the components required to produce progeny virus, HSV1 promoters must successfully mimic the promoters native to the
cell.

In effect, the viral promoters must compete for transcription

factors with cell promoters.
A great deal is known about the elements that combine to form
eukaryotic promoters, and by implication and direct studies, about
HSV-1 promoters as well.

However, because a particular binding

sequence is present in a viral promoter does not necessarily mean
that it fulfills the same role in a virus that it does in a cell.

That is,

the "on" switch and modulation of viral gene expression may differ
subtly from the conditions observed in host promoters.

Because a

sequence exists that may bind a protein factor does not mean that it
plays a regulatory role.
significance is required.

An assay to demonstrate regulatory
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In this thesis research, two separate experimental approaches
were utilized to investigate regulation of this gene during the
infectious cycle:
1. Cell free in vitro transcription was utilized to study the
transcriptional regulation of the VP5 gene.
2.

DNA binding competition studies were employed to identify
and characterize the protein-DNA complexes resulting from
interaction between the cis-acting sequences of the VP5
gene, other viral genes and the proteins that bind to
them.

The goal of this research was to identify cis-acting DNA sequences
and trans-acting protein factors that are involved in the regulation of
leaky-late transcription.

CHAPTER II
MATERIALS AND METHODS

Cells and Viruses
HeLa cells (ATCC #CCL2), derived from a human cervical
epithelioid carcinoma, (adenocarcinoma) were used for preparation
of all nuclear extracts.

HEp-2 cells (ATCC #CCL23), a human

laryngeal epidermoid carcinoma cell line, were used for
of all viral stocks.

preparation

Herpes simplex virus, type I, (HSV-1) KOS strain

(wild type) and vhsl (mutant strain deficient in the virus host shut
off of protein synthesis) were used in preparation of infected cell
extracts.

Preparation of Stock Virus
Stock virus were prepared by infecting nearly confluent
(approximately 85% confluent) HEp-2 cell roller bottle cultures m
Dulbecco's Modified Eagle Medium (DME) plus 1% inactivated calf
serum (Gibco) at low multiplicity (0.02 plaque forming units [pfu] per
cell).

Viral harvest was done when cells exhibited cytopathic effects

indicated by changes in cell morphology (i.e., rounding, loss of
confluency ), typical of viral infection at approximately three days
post infection. Harvest was accomplished by scraping the cells into
the medium.

The cells were pelleted by centrifugation at 4 °C, 2000 x

g for 10 minutes.

The cells were disrupted on ice with the Bran sen
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Sonnifier W-350 in 15 second bursts for two minutes with the
setting at two.

Cell debris was removed by centrifugation for 30

minutes at 2000 x g at 4 °C.

The supernatant liquid containing the

virus particles was stored at -70°C in DME containing10% heat
inactivated fetal calf serum.
The viral titer was determined by plaque assay on Vero cells
(ATCC #CCL81 ), African green monkey kidney cells, grown in
monolayer cultures as described by Millette et al. (40).

Preparation of Nuclear Extracts
Nuclear extracts were prepared as described by Dignam, et al.
(16) or Shapiro (57) except as follows.

HeLa cells were grown in

monolayer roller bottle cultures in DME plus 5% inactivated calf
serum.

Preparation of infected extracts was achieved by infecting

monolayer cultures at a confluency of approximately 80% with HSV1 at a multiplicity of 10 pfu/cell.

Cells were harvested at

approximately eight hours post infection by rinsing the monolayers
twice with ice cold phosphate buffered saline (PBS) and scraping into
cold PBS.

The cells were pelleted by centrifugation at 2000 x g for

ten minutes at 4 °C.
Cycloheximide reversed v hs 1 infected extracts were prepared
as described by Dignam, et al. ( 16) or Shapiro (57).

The infection

protocol utilizing the drugs involved adding cycloheximide (final
concentration of 50 µg/ml) was added to the medium one-half hour
prior to infection.

Virus was introduced at a multiplicity of ten
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pfu/cell.

One and one-half hours post infection, the infecting

suspension was decanted and the cells were overlaid with DME plus
1% inactivated calf serum with cycloheximide, 50 µg/ml.

Five and

one-half hours after infection, actinomycin D was added to the
medium at a final concentration of 5 µg/ml.

Following a 30 minute

incubation, the cycloheximide block was reversed with three washes
of medium containing 5 µg/ml actinomycin D.

Harvesting of the cells

was carried out one and one-half hours following cycloheximide
reversal.

Nuclear extracts were prepared as previously described.

DNA and Plasmids
Plasmid DNA was prepared by the alkaline lysis procedure (4)
with modifications as described in Sambrook et. al. (54). Briefly, this
procedure consists of growing liquid cultures of E. coli containing the
plasmid of interest with the appropriate antibiotic, i.e., ampicillin at a
final concentration of 50 µg/ml.

Plasmids were amplified in late log

phase by adding chloramphenicol to a final concentration of 170
µg/ml.

Bacteria were harvested 12 to 16 hours post amplification by

centrifugation at 4000 x g.

Cells were resuspended in buffer

containing 0.1 M NaCl, 10 mM Tris-Cl, and 1 mM EDTA. Cells were
lysed with lysozyme (10 mg/ml in 10 mM Tris-Cl) followed by 0.2N
NaOH in 10% SDS (sodium dodecyl sulfate).

Following the addition

3M potassium in 5M acetic acid to neutralize the alkaline NaOH/SDS,
the chromosomal DNA and cell debris were removed by
centrifugation. The supernatant liquid containing the plasmid DNA
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was filtered through four layers of cheese cloth and plasmids were
collected by isopropanol precipitation and purified by precipitation
with PEG-8000.
Fragments were isolated from restricted plasmids by the DEAE
paper electroelution method (19).

DNA fragments were labeled at

the 3' ends by Kienow fill-in (54) using [a-32p]dCTP.
Plasmid pKSBBO was made in this lab by the insertion of the
2.24 kB BstEII-BamHI fragment of the BamZ fragment of HSV-1 into
pBR322.

This fragment contains the ICPO gene.

Plasmids pSG22

(23), pHSV106 (39), pVP5(-168)CAT (6), pVP5(-168)CATLl2 (10) and
pJB3 (29), pRB122 (66), pHKg (1), pIMlO and pGTSa2 (33), pU3RIII
and pU3RIII-167 (53) were either previously prepared in this
laboratory or obtained from others.

They are described in Table I.

Enzymes
Restriction endonucleases were purchased from Bethesda
Research Labs, Inc. (BRL) or New England Biolabs, Inc.

Restriction of

DNA was carried out using the lOx reaction buffers provided by the
manufacturers or the appropriate concentration of KGB buffers
(54W).

DNA was digested for two to four hours at 37° with three to

four units enzyme per µg DNA.
In Vitro Transcriptions
In vitro transcriptions were performed as described in Dignam,

et al. (16) and Shapiro (56) except [a-32P]CTP was used.

Briefly,

nuclear extracts were prepaared by one o the above methods.
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TABLE I
PLASMIDS
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pGTSa2
pHKg
pHSV106
plMlO
pJB3
pKSBBO

pRB122
oSG22
pU3RIII
pU3RIII-167
pVP5(-168)CAT
oVP5(-168 lCATLi2

Sall subfragment of
B am HI J fragment
Hindlll K fragment
mao units 0.527-0.592
BamHI Q

pBR322

gB

pBR322

UL37

pBR322

1.7 kB Sall fragment
Smal subfragment of
B am HI J fragment
2.24 BstEII-BamHI
fragment of IRL,
residues 1201-5520
B amHI Z fragment

pBR322
pACYC177

Thymidine
Kinase
gH:L
VP5
gD

pBR322

ICPO

pBR322

EcoRI I fragment
-453 - +80 of 3' LTR of
HIV
-167 - +80 of 3' LTR of
HIV
VP5 promoter -4 to -168
VP5 oromoter

oBR325
pSVIXCAT

IE 4/5
OCP4/a4 7)
UL47
trans-acting
factor
trans-acting
factor
VP5
VP5

pSVIXCAT
oSVOd-CAT
oSVOd-CAT

Transcriptions were carried out in 50mM Tris HCl, pH 8, 10 mM to 12
mM MgClz, 0.6 mM ATP, GTP and UTP, 1 mM CTP, 80 mM KCl, 200
mM DTT (dithiothreitol), 50 µM [a-32p]CTP (10 µCi), 15 to 29 ng/µl
DNA, and nuclear extract (75 µg/ml protein).
mixture was incubated for 60 minutes at 30°C.

The transcription
RNA was purified by

phenol-chloroform-isoamyl alcohol extraction and ethanol
precipitation. The RNA pellets were dried under vacuum for 15
minutes and denatured with glyoxal.

Analysis of RNA was

accomplished by gel electrophoresis for 600 volt-hours in a 1.6%
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agarose gel in phosphate buffer with recirculation as described by
Beck and Millette (2).

The gels were dried under vacuum and

exposed to Fuji RX film for autoradiography at -80°C for 24 to 48
hours.

Gel Mobility Shift Assays
Gel mobility shift reaction mixtures contained 0.5 ng to 1.5 ng
(5000 to 8000 cpm) DNA probe, 2.8 µg poly(dl-dC):poly(dl-dC)
(Pharmacia), and nuclear extract (1.8 µg protein) mixed in a reaction
buffer providing final concentrations of 6 mM Tris-HCl, pH 7 .9, 40
mM KCl, 2 mM EDTA, 0.2 mM DTT (dithiothreitol), 8% (v/v) glycerol

in a total volume of 25 µl.

Following a 30 minute incubation at room

temperature, 2 µl of 0.25% bromphenol blue was added and the
samples were electrophoresed at 4 °C through polyacrylamide gels
made with 4% acrylamide, 0.13% bisacrylamide in a Tris-borate
buffer that was 25 mM Tris base, 25 mM boric acid, and 1 mM EDT A.
Gels were vacuum dried and exposed to Fuji RX films with
intensifying screens.

DNA Competition Binding Assays
The DNA competition binding assays were carried out under
,..

!~

the same conditions specified for gel mobility shift assays except for
the following.

A 40-100 molar excess of unlabelled competitor DNA

added to the reaction mix which was then

incubated at room

temperature for ten minutes prior to adding the radiolabelled probe.
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Then 0.2 to 0.5 ng of DNA probe was mixed into the reaction mixture,
and room temperature incubation continued for an additional 20
minutes.

The samples were then electrophoresed as described above

for gel mobility shift assays.

""

CHAPTER III
RESULTS

I. USE OF AN IN VITRO TRANSCRIPTION SYSTEM TO STUDY HSV-1

~'Y

(y1) GENE TRANSCRIPTION

It is possible to generate RN A from an isolated promoter

sequence via in vitro transcription in a soluble cell free system ( 16,
57).

Using extracts prepared from cells not infected with HSV-1, it is

expected that promoters from HSV-1 a genes would be readily
transcribed.

Because B and By genes require a products for

expression, transcription from these promoters is not predicted
under the same experimental conditions.

A.

Immediate Early

(a)

Genes. But Not Later Classes. Are Transcribed

by a Nuclear Extract from Infected Cells.
Before the regulation of VP5 transcription could be studied by
in vitro assay, it was necessary to demonstrate that it is possible to

generate RNA from HSV-1 promoter templates in soluble cell-free
systems.

This was accomplished by choosing promoters from the

various kinetic classes and subjecting them to transcription with
~

extracts prepared from uninfected HeLa cells by the Dignam protocol
as described.

The ICPO promoter (a gene) transcribed readily in the

soluble cell-free extracts yielding a specific transcript of 1.4 kbp
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(figure 4, lane 4).

However, promoters from the later kinetic classes

transcribed poorly and, at most, yielded only end-to-end transcripts
on a consistent basis.

Thus the tk (p 1) and gB (py) templates gave no

discernible transcripts (figure 4, lanes 3 and 5 respectively).

The

VP5 (py) template gave only low yields of the 1.1 kbp RNA (figure 4,
lane 6).
Repeating this experiment with a new preparation of extracts
from uninfected cells made by the Dignam method yielded results
consistent with the previous experiment (figure 5).

The a promoter

ICPO once again yielded a prominent specific transcript of 1.4 kbp.
(figure 5, lanes 2 and 7).

Promoters of all other kinetic classes failed

to yield any specific RNA products (figure 5, lanes 3, 4, 6, 8 and 9),
including the VP5 promoter (figure 5, lane 5).
As demonstrated from the
m figures 4 and 5, promoters of the

preceding experiments illustrated

p and py

classes supported little

or no transcription in in vitro systems in the absence of HSV-1 a
products.

This is consistent with what is known about the

requirements for herpes virus replication in vivo. Logically, the next
step would be to prepare nuclear extracts which contained a
proteins.

B.
.I

Transcription With Infected Cell Extracts
The simplest and most direct method of enriching a nuclear

extract with early HS V -1 proteins is to prepare the extracts from
cells that have been infected with the virus.

Such extracts were
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23.1
9.4
6.68
4.36

2.32
2.02

0.56

A. Hind

I II

pBR322

gB(~)

tk(~)

!CPO

VP5(~y) III

pBR322

(a)

/

Figure 4. In vitro transcription from various HSV-1 promoters using
a cell free soluble nuclear extract prepared by the Dignam protocol.
Lanes 1 and 7, bacteriophage 'A DNA cut with HindIII as markers.
Lanes 2 and 8, pBR322 DNA cut with Alul as markers. HSV-1 DNAs
used as templates for in vitro transcription and the promoters they
contained are as follows: Lane 3, gB promoter (2.7 kb fragment Sall/
Kpnl fragment of pGTSa2); Lane 4, ICPO promoter (2.9 kb EcoRI/SalI
fragment of pKSBBO); Lane 5, tk promoter (2.04 kb Pvull fragment
of pHSV 106 ); Lane 6, VP5 promoter ( 1.7 kb Sall fragment of
pIM 10 ). End-to-end transcripts are indicated by • and specific transcripts by >.
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Figure 5. In vitro transcription of HSV-1 promoters from various
kinetic classes testing two soluble cell free nuclear extracts
separately prepared via the Dignam protocol. Lanes 2 through 5 are
the results of transcriptions performed with an extract at 3.1 µg per
µl protein concentration. Lanes 6 through 8 are the results of
transcriptions performed with an extract with a concentration of 1.3
µg per µl protein. Lanes 1 and 10, bacteriophage A. DNA cut with
HindIII as a marker. Lanes 2 and 7, ICPO promoter (2.9 kb EcoRI/
Sall fragment of pKSBBO). Lanes 3 and 8, tk promoter (2.05 kb
PvuII fragment of pHSV106). Lanes 4 and 9, gB promoter (2.7 kb
SalI/KpnI fragment of pGTSa2). Lane 5, VP5 promoter ( 1.7 kb Sall
fragment of plMlO). Lane 6, gH:L promoter (1.21 kb Kpnl/Pvull
fragment of pHSV 106 ).
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prepared and tested for in vitro transcription.

They uniformly failed

to yield detectable specific RN A product.
Multiple attempts were made to optimize conditions for
transcription, including substituting other divalent cations (Zn++ and
Ca++) for magnesium, as well as changing the Mg++ concentration.
trials were without success.

All

Representative results of such trials are

seen in figure 6, lanes 3 and 4.

It was interesting to note that there

was a slight difference in RN A produced under conditions of 1OmM
versus 12mM Mg++ (figure 6, all lanes).

Despite the lack of readable

transcripts from transcriptions run using extracts made from
infected cells, there appeared to be materially greater yield of
nonspecific RNA (figure 6, lanes 3 and 4).
conduct subsequent experiments with

I therefore elected to

p and py

promoters with 12

mM Mg++.

C. In Vitro

Transcriptions With Shapiro Extracts

While this work was in progress, a new method for making
HeLa nuclear extracts for cell free transcription systems was
published (57).

The authors asserted extracts produced by this

protocol yield an increased efficiency of transcription initiation
ranging from 2 fold to 20 fold over Dignam extracts.

The major

difference between the Shapiro system and the Dignam system
involved replacing the divalent cations normally found in cell
extraction buffers, principally Ca++ and Mg++ with a mixture of the
polyamines spermine and spermidine.

The authors maintained that

lOmM
.,.------- 12 mM
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Figure 6. In vitro transcription of HSV-1 promoters testing magnesium ion concentrations in extracts prepared via the Dignam protocol. Extracts from mock infected cells were used in lanes 1, 2, 5, 6, 7,
8). Extracts from HSV-1 infected cells were used in lanes 3 and 4.
Lanesl, 3, 5, and 7 were run at 10 mM magnesium. Lanes 2, 4, 6,
and 8 were run at 12 mM magnesium. End-to-end transcripts are
indicated by. and specific transcripts by >.
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the presence of polyamines may more nearly approximate the
intranuclear environment than do buffers containing divalent
cations.

Additionally, the authors proposed that the substitution of

polyamines for divalent cations might eliminate the possible
activation of endogenous DNases within the cell by Mg++ and Ca++. To
determine if Shapiro extracts might provide better transcription of
the later gene classes, I prepared uninfected and infected extracts
according to the published protocol.

These were then tested for their

ability to transcribe from various HSV-1 promoter templates.
The uninfected Shapiro extracts revealed some evidence of
discrete RN A bands from the a promoters (figure 7, lanes 2 and 6).
However, there were no detectable transcripts from promoters of the
later HSV-1 kinetic classes (figure 7, lanes l, 3, 4 and 5).

A

transcription performed with nuclear extracts made from HSV-1
infected cells yielded no detectable product (figure 7, lane 7).
Despite the lack of clearly distinguishable RNA bands, I was
optimistic that it might still be possible to produce a cell free, soluble
system capable of transcribing

J3 and J3y promoters.

The transcription

done with the VP5 and tk promoters yielded more product RNA
(albeit degraded) than had been detected on previous assays.

I

thought it was conceivable that a signal from discrete bands might be
obscured by the heavy degradation, and that it might be possible to
modify transcription conditions to enhance the likelihood of readable
transcripts.
I
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gB( ~2)

ICPO(a)

gD(
tk( ~2)

~y)

gH:L( ~)

IE4/S(a) AHindI II

Figure 7. In vitro transcription using uninfected (lanes 1-6) and
infected (lane 9) nuclear extracts prepared by the Shapiro protocol.
Transcription templates are: Lane 1, gB promoter (2.7 kb Sall/Kpnl
fragment of pGTSal); Lane 2, ICPO promoter (2.9 kb EcoRI/SalI fragment of pKSBBO); Lane 3, VP5 promoter ( 1.7 kb Sall fragment of
plMlO); Lane 4, tk promoter (2.05 kb Pvull fragment of pHSV106);
Lane 5, gD promoter (Smal subfragment of BamHI J); Lane 6, IE4/5
promoter ( 1.89 BamHI fragment of pRB 122); Lane 7, gH:L promoter
(1.21 kb Kpnl/pVull fragment of pHSV 106); Lane 8, bacteriophage A.
DNA digested with HindIII used as a marker. End-to-end transcripts
indicated by • and specific transcripts by >.
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Subsequently, transcription conditions were varied
experimentally in an attempt to optimize discrete bands of product
and minimize RNA fragmentation.

Additionally, attempts were made

to isolate any possible sources of exogenous RNase activity.

These

trials included eliminating the RNase inhibitor (Inhibit-Ace) to
determine if it was effective in decreasing enzymatic RNA
degradation, and eliminating the creatine phosphokinase and
creatine phosphate from the reaction mix as possible origins of
RN ase.

Because I was specifically interested in transcription from

the later promoters, gB

(~)

was used as the template.

These attempts were all to no avail.

Despite the presence of

prominent end-to-end transcripts with uninfected extracts, no
specific RNA products were detected (figure 8, lanes 1, 4 and 6).
Attempts at

transcription using infected cell extracts yielded no

detectable RNA bands (figure 8, lanes 2, 3, 5 and 7).

D. In Vitro Transcriptions using vhs-1 Infected Nuclear
Extracts
One hypothesis explaining the failure of infected cell
extracts to yield discrete RN As is that these extracts contain a vffusinduced nuclease (RNase).

It is known that RNase activity is utilized

by the virus in the process of switching protein synthesis from host
to viral products (30, 31, 32, 61 ).

As previously noted, one of the

mechanisms utilized by the virus to redirect the host biochemistry
away from its own macromolecule synthesis toward viral protein

/
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Figure 8. In vitro transcription testing various reaction conditions
with uninfected and infected nuclear extracts prepared by the
Shapiro protocol. The transcription template in all trials was the gB
promoter ( 1.7 kb SalI/KpnI fragment of pGTSa2). Lanes 1, 3, 4, and
6 were run with uninfected extracts. Lanes 2, 5 and 7 were run
with HSV-1 (KOS strain) infected extracts. Lanes 1 and 2, Shapiro
reaction conditions. Lane 3, uninfected Dignam extract run under
Shapiro reaction conditions. Lanes 4 and 5, Shapiro conditions minus
the RNase inhibitor Inhibit-Ace. Lanes 6 and 7, minus creatine phosphokinase and creaatine phosphate.
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production is the disaggregation of host polyribosomes and
degradation of host mRN As.

This process is mediated by a virion-

specific protein, the VHS protein that is present in the tegument of
the infecting virion, and therefore is introduced into the host cell
with initial penetration of the particle.
The first effort to eliminate the nuclease activity involved the
use of a vhs 1 mutant.

The vhs

mutant is derived from the parental

HSV-1 KOS strain and is defective in the virion-associated host
protein synthesis shut-off.

Cells infected with the vhs 1 mutant m

particular exhibit prolonged mRNA half-life compared to cells
infected with the parental KOS strain ( 61 ).
I decided to attempt to exploit the characteristics of the vhs 1
mutant and produce an extract from infected cells that might be
capable of transcribing from By or y class promoters.

The initial trial

was the production of Dignam extracts from HeLa cells infected with

vhs 1 virus for eight hours.

Transcriptions run with the infected

HeLa extracts revealed no transcription from the infected system.
As previously noted, the VHS protein is a y product, but it is
packaged in the tegument of an infecting virion.

It is released into

an infected cell with initial penetration of the virus.
known that

However, it is

HSV-1 has a secondary host shut-off function that is

coded for by a y gene.

I thought it possible that the degradation

observed on transcriptions might be due to this late viral RNase
rather than the defective VHS protein.

I attempted to exploit this

separation of RNase activities to produce HSV-1 infected extracts

I
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capable of in vitro transcription.
I therefore prepared a Dignam extract with cycloheximide
reversal and actinomycin D block using vhs 1 mutant virus.

The

antifungal agent cycloheximide is a protein synthesis inhibitor, and
the antineoplastic drug actinomycin D blocks transcription.

The

protocol developed involved infecting HeLa monolayers with vhs 1
virus in the presence of cycloheximide.

Because the B and y genes

require a products for protein synthesis (and the secondary v hs
function is mediated by a y gene), this treatment enriches the cell
culture in a mRNAs (32).

Subsequent reversal of the cycloheximide

block in the presence of actinomycin D would result in translation of
a mRN As but prevent transcription of the B or y genes and thereby

prevent expression of all delayed early and late gene expression,
including the RNase activity.
Transcriptions were run utilizing a variety of promoters from
the various HSV-1 kinetic classes with both uninfected and infected,
cycloheximide reversed, actinomycin D blocked nuclear extracts.
Unfortunately, attempts at transcription with these infected nuclear
extracts did not yield any detectable transcription products.

Even

ICPO and IE 4/5, promoters that had consistently produced specific

transcripts from uninfected extracts, did not reveal any RNA bands
(figure 9, lanes 1 through 4 ).

As expected, the gH:L promoter did not

generate discrete RNA (figure 9, lanes 5 and 6). These results can be
explained by the possibility that the extracts prepared from
uninfected cells still contained RNase activity.
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Figure 9. In i-ritro transcription utilizing uninfected and vhs 1 infected nuclear extracts prepared via the Dignam protocol. All extracts were prepared from cycloheximide-reversed, actinomycin D
blocked cells. Transcription templates were: Lanes 1 and 2, ICPO
promoter (2.9 kb EcoRl/Sall fragment of pKSBBO); lanes 3 and 4, IE
4/5 promoter ( 1.89 kb BamHI fragment of pRB122); lanes 5 and 6,
gH:L promoter ( 1.21 kb KpnI/PvuI I fragment of pHSV 106 ). Lane 7,
A. DNA cut with HindIII and used as a marker.
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An alternative explanation for the failure of in vitro
transcription to generate distinct RN A is that the infected cell
It is

extracts contain DNase activity that destroyed the templates.

known that HSV-1 codes for at least one alkaline exonuclease ( 17)
and there may possibly be others.

This led to the question

of

whether, in addition to the documented RNase activity present m
infected cells, there might also be some DN ase activity that destroys
the templates before detectable products were present.

Therefore, a

series of experiments was devised to address this question.
The basic approach of these experiments was to incubate DNA
under transcription reaction conditions for varying increments of
time from zero to 60 minutes with extracts made of infected and
mock infected cell nuclei.

To differentiate between exonuclease and

endonuclease activity, intact, covalently closed circular plasmid DNA
(pBR322) was used in half the trials (figure 10, lanes 4, 6, 8, 10, 12,
14, 16, and 18). Linear DNA, pBR322 opened at the EcoRI site was
used in the other half (figure 10, lanes 5, 7, 9, 11, 13, 15, 17, 19).
The possibility of DNase activity in the nucleic acid purification
portion of the experiment was ruled out by incubating intact and
linear pBR322 for 60 minutes in Tris-EDT A buffer and extracting
with phenol-chloroform-isoamyl alcohol (PCIA) by the usual
technique.

Finally, to test for the presence of nuclease activity in the

transcription buffer itself, an additional 60 minute incubation of
linear and uncut DNA in transcription buffer alone was done.

This
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Figure 10. Linear (L) and circular (U) pBR322 incubated with
Dignam nuclear extracts from HSV-1 (KOS strain) infected (H) or
uninfected (M) HeLa cells. Plasmid DNA was either left uncut or
linearized at the EcoRI site and incubated under transcription conditions for the indicated time periods. Following incubation, the DNA
was extracted with phenol-chloroform-isoamyl alcohol (PCIA), then
CIA, and purified by ethanol precipitation. The DNA was redissolved in Tris-EDT A, pH 7.4, electrophoresed on an agarose gel, and
visualized by ethidium bromide staining. Lanes 1 and 20, bacteriophage A- DNA restricted with HindIII. Lane 2, uncut pBR322. Lane
3, pBR322 linearized at the EcoRI site. Lanes 4 through 7, DNA incubated approximately 10 seconds. Lanes 8 through 11, DNA incubated 20 minutes. Lanes 12 through 15, DNA incubated 60 minutes.
Lanes 16 and 17, DNA plus transcription buffer without added
nuclear extracts. Lanes 18 and 19, DNA plus transcription buffer
without added nuclear extracts and PCIA extraction.
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last trial was not extracted with PCIA.

The fate of the DNA was then

determined by agarose gel electrophoresis (figure 10).
Interestingly, these tests revealed rapid degeneration of
circular DNA in all nuclear extract incubations (figure 10, lanes 4, 6,
8, 10, 12, 14).

The linearized plasmid DNA survived degradation to

some extent in all extracts tested (figure 10, lanes 5, 7, 9, 13, 15).
While the preceding experiment did not confirm our suspicions
about a DNase activity destroying linear templates in the
transcription mix, it effectively closed the door on pursuing another
alternative that had been under consideration, the use of a circular
construct as a transcription template.
Despite repeated attempts at manipulating conditions, virus
and extracts, I was unsuccessful in achieving the goal of this avenue
of inquiry--successful in vitro transcription from cell free soluble
extracts of the VP5 promoter.

It was decided, therefore, that further

elucidation of the viral transcription using nuclear extracts was
beyond the scope of the current question, and I elected to pursue
another course of inquiry.

2. USE OF COMPETITION BINDING ASSAYS TO STUDY VP5 LEAKYLATE-DNA BINDING PROTEIN INTERACTIONS
Shin Chen, working in the Millette laboratory, identified a
sequence located between -64 and -75 relative to the VP5 cap site
that is important in transcriptional regulation (figure 11 ).

It was

found that this site bound a cellular factor (LBF) which, by DNasel
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footprint analysis was found to bind to the sequence
GGGCCATCTTGAA.

This sequence was provisionally designated the

leaky-late binding sequence (LBS).

Deletion or mutation of this

sequence resulted in decreased expression from the VP5 promoter m

-1&3 CAAT

-4

1BS

m-1

I

~

'i'c'rrc:c'roGG~~~~~
~.AJ:iGG.JYX:X:; 'l"GC:t;-~ 'l'GG'l"C:O:;X;GT H.;Jl.,,JICITJCJJ,

-100

-90

-BO

-7'0

'1"GGGCAGOX
-8J

Fi~ure

11. VP5 promoter identifying the putative leaky
late binding sequence.

transient expression assay studies with HSV-1 superinfection (10).
DNA binding studies carried out in the Millette laboratory revealed
that this VP5 sequence forms similar complexes with both infected
or uninfected cell nuclear extracts, yielding two major complexes:
Complex A, the slower moving band, and Complex B, the faster (10).
Computer analysis of the HSV-1 DNA sequence identified
similar sequences in the promoters of the genes for glycoprotein D
(36), and in the unique long 37 and unique long 46 (UL37 and UL46)
genes (37).

Additionally, a sequence exhibiting high homology to the

LBS was identified in the coding (internal) portion of the UL37 gene.
Similar sequences are also found in the human immunodeficiency
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virus (HIV) long terminal repeats (LTRs).

However, none of these

sequences are identical to the identified putative LBS (table II).
I chose to investigate the following question:

Does the cellular

protein LBF bind to any of the above sites and therefore possibly

TABLE II

i!'l!llililflilfl

111'1111•111~1111
HSV-1 SEQUENCES
VP5

LBS Core Sequence
GGGCCATCITGMTGCAC

-70 (Cap)

gD

GGGCCATtTTacg

-63 (Cap)

gB

GGCCATCgTcgA
GcCCgTCTTtgAT

+134 (Cap)
-249 (Cap)

UL46

GGGCCATggG

-55 (ATG)

UL37

GGGCCATtTgGg

-279 (Cap)

UL37
(internal coding
sequence)

GcGCCA1CITGA

+610 (ATG)

HIV SEQUENCE
HIV (-168

.TCTTGAA

-134 <Ca

play a role in the expression of the corresponding genes?

With this

question answered, it would then be possible to do a sequence
comparison of the promoters that exhibited competition and deduce
a consensus sequence for the binding of this protein.

In addition,

this analysis would provide clues as to whether similar binding sites
are involved in the regulation of other viral genes.

42

A series of DNA binding competition experiments was designed
m which the promoters and other DNA fragments exhibiting
sequence similarities to the VP5 LBS would be incubated with DNA
containing the VP5 sequence and nuclear extracts under DNA binding
conditions.

In binding studies, DNA containing the sequence of

interest is labeled with radioactive phosphorus (32 P) by Klenow fillin and subsequently incubated with nuclear extracts under
conditions that allow DNA binding proteins to adhere to the labeled
probe.
gel.

The reaction mix is then electrophoresed on an acrylamide

In this assay, the DNA that is bound by protein will migrate

through the acrylamide at a rate that is slower than unbound probe
DNA.

After the gel is dried, it is exposed to x-ray film and the

radioactively labeled DNA probe will cause a darkening of the film at
a point corresponding to the location of the DNA or DNA-protein
complex in the gel.
In competition experiments unlabeled DNA, the competitor, 1s
~

included in large molar excess over the probe in the reaction mix
with limited amounts of protein.

The basic idea is that sequences

exhibiting homology to the DNA that is bound by a particular protein
will themselves bind that same protein, i.e., they will compete with
the probe for the limited DNA binding protein.

If competition occurs,

then a decreased signal from the labeled DNA-protein complex
results on the autoradiogram.

The stronger the competition, the

weaker the signal from the bound probe, with the strongest
competitor possible being the unlabeled homologue of the probe
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DNA.
The first problem was to design the experiment so that the
detection of weak competition is possible.

Even under optimal

competitive conditions, i.e., large molar excess of homologous DNA,
there is often an appreciable signal from the protein-bound probe.

It

therefore can be difficult to detect competition at some level less
than what would be expected from a labeled homologue.
sensitivity of the assay needed to be maximized.

That is, the

It is imperative to

avoid an excess of protein, or competition will not cause a decreased
signal from the probe.
To accomplish this, a series of experiments was carried out in
which a potential competitor was utilized to define conditions for
subsequent studies.

The glycoprotein D promoter fragment contains

a sequence homology to eight out of ten bases with the VP5
promoter sequence of interest.

If this segment of the gD promoter

was bound by the putative leaky-late binding factor, I thought it
likely that competition would occur, but at some degree less than
that of an unlabeled VP5 homologue.

Therefore, the gD promoter

was used to define conditions for the competition studies.

Detectable

competition was represented as a slightly fainter signal in complex A,
and a somewhat greater difference in signal strength at complex B.
This competition occurred between gD and VP5 under the conditions
of approximately 0.75 µg protein with a 40-fold molar excess of gD
DNA.

An example of such competition with the gD promoter can be

seen in figure 12, lane 6 and 7.
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Figure 12. Competition binding of labeled VP5 promoter versus
unlabeled DNA fragments. DNA binding competition was carried out
with 1.8 µg of protein of infected nuclear extracts as described. A, B,
and P, complexes A, B and free probe, respectively. Lanes 1 and 2,
free probe. Lane 3, labeled VPS promoter without competitor. Lanes
4 and 5, 40-fold and 60-fold molar excesses of unlabeled VPS promoter. Lanes 6 and 7, 40-fold and 60-fold molar excesses of glycoprotein D promoter. Lane 8, 40-fold molar excess of HIV promoter (+ 1
to -423). Lanes 9 and 10, 40-fold and 60-fold molar excesss of HIV
promoter (+ 1 to -167).
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Competition studies were subsequently performed with 0.75 µg
protein in which all the above-mentioned sequences were tested
against the VP5 LBS.

As expected, the degree of competition

declined with decreasing homology between the LBS and the
competing DNA.

In an attempt to detect weak competition, the

quantity of competitor excess was titrated against the LBS and DNA
binding protein in the competition mix.
The initial experiment involved running competition studies
with labeled VP5 probe versus unlabeled homologue as a positive
control.

Additionally, DNA containing a promoter for a gene coding

for a trans-acting factor located in the 3' long terminal repeat (LTR)
of the human immunodeficiency virus (HIV) was included.

This HIV

promoter exhibited a region of homology with only the terminal 7 of
12 bases in the proposed LBS (table II).
Competition was detectable in all cases, although it varied with
respect to the strength of competition and with respect to which of
the two major complexes, A or B, was competed against more
strongly.

As expected, the unlabeled VP5 homologue exhibited the

strongest competition, (figure 12, lanes 4 and 5) but with the
stronger competition occurring against the upper band, complex A.
The glycoprotein D promoter competed as expected against the VP5
fragment, but with a stronger signal reduction occurring in the faster
moving complex B (figure 12, lanes 6 and 7).
The HIV fragments also exhibited competition, although it was
somewhat weaker than the competition exhibited by the other

46
fragments.

This was not unexpected because the HIV sequence

exhibits homology with only the terminal seven of 12 bases of the
putative LBS.

Of interest is the difference in competition exhibited

by the two HIV fragments.

Both of these pieces of DNA originate

from the same portion of the viral genome, the only difference
between them is that the HIV promoter fragment in figure 12, lane 8
contains 256 bases upstream from the cap site that are not present
in the other HIV fragment run in lanes 9 and 10 in figure 12, i.e., + 1
to -423 versus +1 to -167.
To verify the competition between the VP5 fragment and the
HIV fragment, another test was run utilizing a 100-fold excess of the
small (-167 to + 1) HIV promoter (figure 13, lane 4) against an 80fold excess of the unlabeled VP5 competitor (figure 13, lane 3).

As

demonstrated previously, there was stronger competition against
complex A from the VP5 fragment.

The same phenomenon is

exhibited with respect to the HIV fragment (figure 13, lanes 3 and
4).

Computer search had revealed the presence of potential
homologueues of the VP5 LBS in other HSV-1 genes.

To determine if

these too bound LBF, further competition binding studies were
performed to assess whether these sequences bound the same
cellular factor bound by VP5 LBS.
As seen in previous experiments, the HIV sequences competed
with the VP5 fragment, although weakly (figure 14, lanes 4 and 5).
With respect to the herpes sequences, it was interesting to note that
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Figure 13. Competition binding of labeled VPS promoter versus
unlabeled DNA fragments. DNA binding competitions were carried
out with 1.8 µg of protein infected nuclear extracts as described. A, B
and P indicate complexes A, B and free probe respectively. Lane 1,
free probe. Lane 2, labeled VPS promoter without competitor. Lane
3, 80-fold molar excess of unlabeled VPS promoter. Lane 4, 100-fold
excess of HIV promoter (+ 1 to -167).
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Figure 14. Competition binding of labeled VPS promoter versus
unlabeled DNA fragments. DNA binding competition was carried out
with 1.8 µg of protein of infected nuclear extracts as described. A, B
and P indicate complexes A, B and free probe respectively. Lane 1,
free probe. Lane 2, labeled VPS promoter without competitor. Lane
3, 40-fold molar excess of VPS homolog. Lane 4, 80-fold molar excess of HIV (+1 to -423 ). Lane 5, 80-fold molar excess of HIV (+1 to 167). Lane 6, 100-fold molar excess of UL37 (+203 to -415). Lane 7,
100-fold molar excess of UL37 coding region (+333 to +1019 ). Lane
8, 100-fold molar excess of UL46 promoter (+118 to -161 ). Lane 9,
100-fold molar excess gB promoter (+134 to -249 ).
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the internal UL37 sequence exhibiting homology to the VP5 coding
sequence exhibited stronger competition than did the promoter
sequence (figure 14, lanes 6 and 7).

Both UL46 and glycoprotein B

exhibited some weak competition, more remarkably against complex
B than against complex A (figure 14, lanes 8 and 9).
In general, the HSV-1 promoters appeared to compete more
strongly against complex B, while the HIV, though weakly
competitive, exhibited more striking results against the larger
complex A ..

CHAPTER IV
CONCLUSIONS

1. IN VITRO TRANSCRIPTION
The herpes simplex virus VP5 promoter has, so far, been
difficult to transcribe in in vitro

transcription systems.

Repeated

attempts at manipulating experimental conditions and trials with
different strains of virus were unsuccessful.

While it is not possible

to definitely ascribe this lack of success to any one attribute of viral
physiology, it is possible to hypothesize about the negative results.
Herpes simplex virus has a well documented, though poorly
understood system by which host protein synthesis is redirected to
the production of viral progeny (30, 31, 32, 50, 60).

This system is

known to degrade host mRNA, and it has been hypothesized that this
RNA destruction is necessary for the efficient switching of
transcription between the temporal classes.

The persistent presence

of what is construed to be RNase activity in the transcription mixture
prepared from infected extracts is the most obvious reason for the
lack of readable transcripts.

Multiple attempts that were made to

circumvent this problem and all proved unsuccessful.
Another cause for lack of readable transcripts originating from
late promoters may be the failure of the template itself to survive
long in the transcription mix from infected cells.

It is interesting that
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the surviving templates in the incubation experiments (figure 10)
were linear, while the circular plasmids were degraded.

An

endonuclease activity is the obvious explanation for the failure of
intact circular DNA to persist in the transcription mix.

However, the

possible reasons for the preferential degradation of the formerly
circular template over a linearized template incubated under the
same circumstances remains elusive.
The presence of high molecular weight DNA at the origin in
figure 10, lanes 4 and 6 is interesting.

This could possibly indicate

the presence of a DNA binding protein in the nuclear extract.
Incubation with nuclear extract for a few seconds conceivably could
permit protein binding.
The reasons for the failure of the Shapiro extracts to produce
stable transcripts is not understood.

There was one major difference

between our protocol and the one published by the author.

Because

it was necessary to make infected extracts, our cells were grown in a
monolayer culture in roller bottles.

The published protocol specified

the use of cells grown in suspension in spinner cultures.

It may be

that the physical and biochemical differences between the two HeLa
cell lines were significant contributors to the failure to produce
stable mRNAs by in vitro transcription.

2. DNA BINDING COMPETITION STUDIES
The gel mobility assays were somewhat more successful.

As

demonstrated in figures 13, 14, and 15, competition occurred in all
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cases, although at different strengths.

In general, the herpes

promoters exhibited a greater level of competition than did the HIV1 promoter, although the gB promoter was competitive only at a very
great (100 fold) molar excess.
It was interesting to note that were was a difference in

competition between the HIV preparations.

In some cases the HIV

DNA competed only weakly (figure 12, lanes 8, 9 and 10; figure 14,
lanes 4 and 5).

However, in cases in which competition was

observed, the promoter from pU3RIII competed more strongly than
pU3RIII-167.

It is notable that he larger plasmid, pU3RIII, contains

256 bases upstream that are not present in pU3RIII-167.

Analysis

of this sequence reveals three areas of partial homology to the
putative LBS located at -351, -398 and -411 that are not carried by
the smaller plasmid (figure 16).

Until it is demonstrated otherwise,

these regions of possible LBF binding must be considered potentially
responsible for the different levels of competition exhibited by the
HIV fragments.
It is interesting to note the differences in competition between
the UL37 internal coding sequence and the UL37 promoter sequence.
The internal sequence exhibits ten base pairs of homology with the
VP5 LBS.

In contrast, the promoter sequence exhibits three base

pairs that are not homologous at positions #8, #10 and #12 of the
VP5 LBS (table 3).

The difference in competition between these two

fragments of UL37 suggests that these three bases are important in
binding.

It should be noted that the two fragments of HSV-1 UL37
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GAACT
AGATGG
GACAAGATATCCTr.QATCTGTGGATCTACCACACACAAGGCTAcrrccrrGATTAGCAGA
-411

-398

CLCGGT
ACTACACACCAGGQCCAGGGGTCAGATATCCACTGACCTTTGGATGGTGCTACAAGCTAG
-351

TACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAGAGAACACCAGCITGTTAC
ACCCTGTGAGC'CTGCATGGATGGATGAC'CCGGAGAGAGAAGTGITAGAGTGGAGGTITGA
ACCGGG
AAGTT
CAGC'CGCCTAGCATITCATCACGTGGCCCGAGAGCTGCATCGGGAGTACITCAAGAACTG
-159

LBS homology

CTGATATCGAGCTTGCTACAAGGGACITICGCfGGGACTITC'CAGGGAGGCGfGGCCTG
GCGGGACTGGGGAGTGGCGAGC'CCTCAGATC'CTGCATATAAGCAGCfGCI Ill IGCCTGfACT
Fi~ure

15. HIV sequence from -423 to +1 of the 3' long
terminal repeat.

DNA are very close to the same size (686 base pairs for the internal
sequence versus 616 base pairs for the coding sequence).

Thus the

possibility of nonspecific DNA binding contributing to the difference
in competition is not great.
Based on the above data, the following consensus is proposed
for the LBS: GGGCCATNTTGA (table III).
After this work was completed, several authors reported
successful isolation of a protein that binds to a similar sequences m
several different genes

(45, 50, 56, 58)..

This protein, alternately

named YYl, NF-El, and NF-B among others, has been reported to
function as a transcription activator in the context of ribosomal
protein promoters (56), and as a transcriptional repressor when
binding the human immunoglobulin x:3' enhancer and the human
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TABLE III

VP5

IG

G G

G G G

B
UL46
UL37 - Promoter
UL37 - Codin
HIV

I
G G G
G
G

c
c
c
c
c
c
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c
c
c
c
c
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A

T

A
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A
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t

T

A

T

c
c

T

T

T

T

T

g

Gr:AIA
G

Table 3. The proposed binding sequence of fragments with
homology to the LBS. Upper case letters and shading indicate
base pair homology. Lower case letters and unshaded areas
indicate lack of homology.
immunoglobulin heavy chain µEl site (45).

Subsequent work carried

out by Lisa Mills in the Millette lab has demonstrated that the
cellular protein LBF is the same molecule as transcription factor YYl
(41) and that this protein plays a role in the HSV-1

py

genes by viral

fact)ors.

3. SUMMARY
In summary, I have presented several lines of experimental
investigation that have indicated that genes of the

p, py,

and

y

kinetic

classes of herpes simplex virus type 1 are resistant to analysis by in
vitro transcription.

HSV-1 genes of the a class require only the viral
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protein a TIF in addition to cellular transcription factors for
activation.

Because aTIF is packaged in the tegument of the infecting

virion, it is released into the host cell with initial viral penetration.
Therefore, it is present at the onset of the transcription of a genes.
However, promoters of the later genes require a gene products.
Attempts at preparing nuclear extracts capable of transcribing these
~y

later promoters in general, and from
uniformly unsuccessful.

promoters in particular, were

This failure to generate specific RNA may be

attributable to persistent RNases in the nuclear extracts which are
coded for by the viral DNA and are therefore endogenous to the
virus.

Further attempts at in vitro transcription will necessarily

depend upon the successful repression of these virus specific
enzymatic activities.
DNA binding competition studies revealed that an assortment
of herpes simplex virus type 1 genes exhibiting partial homology to
the LBS of the HSV-1 VP5 promoter competed for the same protein
factor.

Additionally, a short fragment of human immunodeficiency

virus from the 3' long terminal repeat containing a seven base pair
homology exhibited weak competition.
consensus sequence was proposed.

Based on this work a

Subsequent work in the Millette

laboratory demonstrated that this sequence binds a ubiquitous
cellular transcription factor, alternately named YYl.

CHAPTERV
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